In a report released today, Michael Matson from Needham assigned a Buy rating to Inogen (NASDAQ: INGN), with a price target of $215. The company’s shares opened today at $171.85.
Matson observed:
“We believe a short report has created an excellent entry point for INGN shares. We address the report’s major points below.”
According to TipRanks.com, Matson is a 5-star analyst with an average return of 10.2% and a 63.2% success rate. Matson covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Cardiovascular Systems, and Zimmer Biomet Holdings.
Inogen has an analyst consensus of Strong Buy, with a price target consensus of $180.
See today’s analyst top recommended stocks >>
Inogen’s market cap is currently $3.66B and has a P/E ratio of 148.85. The company has a Price to Book ratio of 14.87.
Based on the recent corporate insider activity of 73 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of INGN in relation to earlier this year. Most recently, in March 2018, Byron Myers, the EVP Sales & Mkt of INGN bought 5,798 shares for a total of $13,915.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Inogen, Inc . engages in the development, manufacture, and marketing of portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Its products consists of Inogen One G4 system, Inogen One G3 system, Inogen One G2 system, and Inogen at Home. The company was founded by Alison Perry, Alison Bauerlein, Brenton Taylor and Byron Myers on November 27, 2001 and is headquartered in Goleta, CA.
